Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy

International Urology and Nephrology

Volumn 40, Issue 2, 2008, Pages 321-327

  Kolla, Surendra B ^a   Seth, Amlesh ^a   Singh, Manoj K ^a   Gupta, Narmada P ^a   Hemal, Ashok K ^a   Dogra, Prem N ^a   Kumar, Rajeev ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Bladder cancer; Her2 neu; Radical cystectomy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BLADDER TUMOR; CANCER INVASION; CYSTECTOMY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; TRANSITIONAL CELL CARCINOMA;

CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTOR, ERBB-2; URINARY BLADDER NEOPLASMS;

EID: 52649176386     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-007-9283-x     Document Type: Article

References (22)

1. Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of bladder cancer: long-term results in 1054 patients. J Clin Oncol 19:666-675
2. Yamamoto T, Ikawa S, Akiyama T et al (1986) Similarity of protein encoded by the human c-erb-B2 gene to epidermal growth factor receptor. Nature (London) 319:230-234
3. Graus-Porta D, Beerli RR, Daly JM, Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647-1655
4. Stern DF (2000) Tyrosine kinase signaling in breast cancer; ErbB family receptor tyrosine kinase. Breast Cancer Res 2:176-183
5. McCann A, Dervan PA, Johnston PA et al (1990) C-erbB- 2 oncoprotein expression in primary human tumors. Cancer 65:88-92
6. Zhau HE, Zhang X, von Eschenbach AC et al (1990) Amplification and expression of the c-erb B2/neu protooncogene in human bladder cancer.Mol Carcinog 3:254-257
7. Kruger S, Weitsch G, Buttner H et al (2001) Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol 21:981-987
8. Hermanek P, Sobin LH (1987) TNM classification of urinary bladder tumours, 4th edn. Springer, New York
9. Mostofi FK, Sobin LH, Torloni H (1973) Histological typing of urinary bladder tumours. World Health Organization, Geneva
10. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159-3167
11. Lu Z, Jiang G, Blume-Jensen P, Hunter T (2001) Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol 21:4016- 4031
12. Gandour-Edwards R, Lara PN Jr, Folkins AK et al (2002) Does Her2/neu expression provide prognostic information in patients with advanced urothelial carcinomä Cancer 95:1009-1015
13. Underwood M, Bartlett J, Reeves J et al (1995) C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res 55:2422-2430
14. Jimenez RE, Hussain M, Bianco FJ Jr et al (2001) HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 7:2440-2447
15. Cobleigh MA, Vogel CL, Tripathy D et al (1999) Multinational study of the efficacy and safety of humanized anti- HER2 monoclonal antibody in women who have HER2- overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648
16. Salmon D, Leyland-Jones B, Shak S et al (1998) Addition of Herceptin to first line chemotherapy for Her2 over expressing metastatic breast cancer markedly increases anticancer activity: a randomized multinational controlled phase III trial. Proc Am Soc Clin Oncol 17:98
17. Lebeau A, Deimling D, Kaltz C et al (2001) HER2 analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19:354-363
18. Schraml P, Kononen J, Bubendorf L et al (1999) Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 5:1966-1975
19. Miyamoto H, Kubota Y, Noguchi S et al (2000) C-erbB-2 gene amplification as a prognostic marker in human bladder cancer. Urology 55:679-683
20. Lonn U, Lonn S, Friberg S et al (1995) Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res 1:1189-1194
21. Pegram MD, Lipton A, Hayes DF et al (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671
22. Bacus SS, Gudkov AV, Lowe M et al (2001) Taxolinduced apoptosis depends on mitogen activated protein kinase (MAP-K) pathways (ERK and p38) and is independent of p53. Oncogene 20:147-155